Brand's Off-Label Promotion: Valuable Tool For Generics
December 8, 2011, 1:07 PM EST
Law360, New York (December 8, 2011, 1:07 PM EST) -- On Nov. 3, GlaxoSmithKline PLC announced that it will pay $3 billion to settle civil and criminal allegations that it promoted the drug Avandia for off-label uses. This is only the latest in a long list of such settlements. Since 2004, pharmaceutical companies have paid a combined $13 billion to settle charges of off-label promotion of numerous brand-name drugs.
A little-appreciated consequence of this promotional activity is its potential impact on patent infringement claims brought by brand companies against generics. Experience from the recently settled multibillion-dollar patent...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.